Navigation Links
Covance Reports Second Quarter Net Revenue of $592 Million, Pro Forma EPS of $0.78 and Record Adjusted Net Orders of $776 Million
Date:7/30/2013

ngs(81)(81)Net (loss) income $
(12,677)$
,530$
39,723$
2,746$
-$
36,322Basic (loss) earnings per share$
(0.23)$
.12$
.73$
.05$
.67Weighted average shares outstanding - basic54,184,96654,184,96654,184,96654,184,96654,184,966Diluted (loss) earnings per share$
(0.23)$
.12$
.73$
.05$
(0.02)$
.65Weighted average shares outstanding - diluted54,184,96654,184,96654,184,96654,184,9661,500,115(4)55,685,081(1) Represents costs incurred to better align capacity to preclinical market demand and reducecost structure.(2) Consists of inventory impairment ($20,781), goodwill impairment ($17,959) and impairment ofequity investment ($7,373).(3) Represents results of operations at sites where wind-down activities have commenced.(4) Reflects inclusion of impact of common stock equivalents in computation of diluted earningsper share as GAAP loss transitions to Pro Forma income. COVANCE INC.GAAP to Pro Forma ReconciliationYTD Q2 2013(Dollars in thousands, except per share data)(UNAUDITED)AdjustmentsGAAP Restructuringand Other Cost Reduction Activities (1)Other
Items (2)Pro FormaNet revenues$ 1,172,497$ 1,172,497Reimbursable out-of-pocket expenses105,814105,814Total revenues1,278,311--1,278,311Costs and expenses:  Cost of revenue830,459830,459  Reimbursable out-of-pocket expenses105,814105,814  Selling, general and administrative179,396(10,101)169,295  Depreciation and amortization62,881(2,082)60,799Total costs and expenses1,178,550(12,183)-1,166,367Income from operations99,76112,183-111,944Other (income) expense, net:  Interest expense, net1,8751,875  Foreign exchange transaction loss, net1,0291,029  Gain on sale of investments(16,400)16,400-Other (income) expense, net(13,496)-16,4002,904Income before taxes113,25712,183(16,400)109,040Taxes on income24,0973,894(5,746)22,245Net income $
89,160$
8,289$
(10,654)$
86,795Basic earnings per share$'/>"/>
SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Covance Central Laboratory Services Again Ranks #1 in Global Investigator Satisfaction Survey
2. Covance To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
3. Covance Reports First Quarter Net Revenue Growth Of 9.3% To $580 Million, Pro Forma EPS Of $0.75 And Adjusted Net Orders Of $716 Million
4. Covance Expands Singapore Central Laboratory by 50 Percent to Meet Clients Increased Asia Pacific Focus
5. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2013 Financial Results Conference Call
6. Covance To Present At The Citi 2013 Global Healthcare Conference
7. Covance To Present At The Leerink Swann Global Healthcare Conference
8. Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
9. Covance To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
10. Covance Reports Third Quarter Pro Forma Net Revenue Of $542 Million, Pro Forma EPS Of $0.72 And Adjusted Net Orders Of $701 Million
11. Covance to Present at the Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... Pa. and STOCKHOLM , ... (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced ... (CHMP) of the European Medicines Agency (EMA) has adopted ... clostridium histolyticum) for the treatment of adult men with ... of at least 30 degrees at the start of ...
(Date:12/22/2014)... 22, 2014  Eiger BioPharmaceuticals Incorporated announced the ... lonafarnib in patients with chronic hepatitis delta virus ... National Institutes of Health (NIH) Clinical Center in ... randomized, placebo-controlled, dose ascending study evaluated two doses ... mg twice daily for 28 days.  "This proof-of-concept ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... (Pink Sheets: MDBX ) ( www.thedispensingsolution.com ), ... to MDBX.  The company previously announced that their name ... The company is a leader in the design, manufacture ... The free-standing unit features 60 or more slots that ...
... 2011 This year, the melanoma community saw the first ... This major step forward will give more than 400 party-goers ... Gala.  They will gather at the Trump National Golf Club ... these cutting-edge advances and raise money for future research through ...
Cached Medicine Technology:MedBox Announces Ticker Symbol Change 2Washington, D.C. Melanoma Patient Community Celebrates Treatment Advances 2Washington, D.C. Melanoma Patient Community Celebrates Treatment Advances 3
(Date:12/25/2014)... The microscopy market is estimated ... reach $5,756.0 million by 2019. Optical microscopy is ... electron microscopes product segment is expected to show ... Rising focus on nanotechnology, technological advancements, and increasing ... market. , Get Full Copy of Report @ ...
(Date:12/25/2014)... The click strand woven bamboo flooring ... the business announces a click strand woven bamboo ... 2015. , Click strand woven bamboo flooring replicates ... well-known brand in the bamboo industry. It promises ... bamboo flooring supplier. , “We are happy to ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The report ... 2023” focuses on the current treatment landscape, unmet needs, ... market. TS-1 is an anti-cancer drug which is typically ... and is also used for treating gastric cancer and ... otastat potassium. The drug was first approved in 1999 ...
(Date:12/25/2014)... three months the trends for evening dresses shift ... one of the hottest styles in the next few months.” ... releases 26 A-line sweetheart evening dresses, and announces the availability ... are trying our best to help a lady to show ... affordable prices, we provide discounted delivery costs to our customers ...
(Date:12/25/2014)... 2014 Recently, Dylan Queen, a famous ... released its collection of discounted prom dresses, most of ... senior spokesman of the company, the promotion is valid ... is to expand the UK market. , The prom ... colors, lengths, and styles: A-line strapless, empire strapless chiffon, ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... International Cancer Research team has come out with the startling ... development of tumors in mice. This discovery could be vital ... molecules work by blocking the hormones that are essential for ... they strangle the tumor by blocking blood and nutrient supply ...
... turning their backs on tanning amid growing concerns over skin ... survey shows that teenagers are resisting the urge to tan ... 5,073 Australian adults and 699 Australian teenagers aged 12 to ... that 68 % of those aged 12-17 said they had ...
... part of the school curriculum from Class IX in all ... the age of 25. The new curriculum would be made ... the Human Resource Department of Government of India and National ... ministry has also made it compulsory to train teachers on ...
... have reacted with skepticism to a British man's claims that he ... some relief. // , ,In what is assumed as a ... now available in India. , ,This medicine is provided in ... that it would help the infected people to lead a much ...
... are unconcerned with the effect of their habit on the ... the damage // that smoking caused to the tongue or ... strangely reluctant to change their habits. This is of particular ... a massive awareness campaign as a part of the Mouth ...
... a doctor's permission is good at any time of life, ... study. // ,Thomas Foster and other scientists from the McKnight ... of rats that had lived to old age. Some were ... , ,Scientists examined chemical compounds in 41 tissue samples ...
Cached Medicine News:Health News:Aussie teens applauded for declining sun tan 2Health News:Regular light exercise slows down aging of the brain 2
Cushing-Hopkins periosteal elevator, Gutsch handle, blade width 7/16" (11 mm), length 7 5/8" (194 mm)....
Barr periosteal elevators....
Seldin periosteal elevators....
Williger periosteal elevators....
Medicine Products: